Related Experiment Videos
Considerations in selecting protease inhibitor therapy.
Brian A Boyle1, Richard A Elion, Graeme J Moyle
1Weill Medical College of Cornell University, New York, NY 10021, USA. brianboylemd@yahoo.com
AIDS Reviews
|February 11, 2005
Summary
Highly active antiretroviral therapy (HAART) with protease inhibitors has improved HIV outcomes. Newer protease inhibitors offer simpler, more effective, and safer treatment options for HIV patients.
Area of Science:
- Infectious Diseases
- Virology
- Pharmacology
Background:
- Protease inhibitors (PIs) are crucial components of highly active antiretroviral therapy (HAART) for HIV-infected individuals.
- Early PIs presented challenges including limited efficacy, side effects, complex regimens, and cross-resistance.
- Significant advancements have been made in PI development over the last decade.
Purpose of the Study:
- To review the evolution and impact of protease inhibitors in HIV treatment.
- To highlight improvements in PI-based HAART regimens.
- To emphasize considerations for selecting optimal PIs for long-term patient management.
Main Methods:
- Review of clinical literature and drug development advancements in protease inhibitors.
- Analysis of efficacy, tolerability, and resistance profiles of early and newer PIs.
- Consideration of treatment regimen complexity and patient-centered factors.
Main Results:
- Advances like ritonavir boosting and once-daily dosing PIs have enhanced HAART.
- Newer PIs demonstrate improved efficacy, reduced toxicity, and lower resistance risk.
- Simplified and better-tolerated PI therapy is now achievable.
Conclusions:
- Modern protease inhibitor-based HAART offers significant benefits over earlier regimens.
- Individualized selection of PIs, considering drug characteristics and patient preference, is key.
- Optimizing PI choice maximizes long-term treatment success and tolerability in HIV management.